Stereotactic body radiation therapy (SBRT) is an evolution of stereotactic radiosurgery that delivers high-dose radiation to tumors in fewer fractions than conventional radiotherapy. It requires extra-ordinary care due to the precision needed to target tumors while sparing surrounding tissues from damage. SBRT has shown efficacy in treating various tumor types including lung, liver, spine, pancreas and prostate cancers with acceptable toxicity risks when proper quality assurance procedures and motion management techniques are followed.
In this document
Powered by AI
Overview of Stereotactic Body Radiation Therapy (SBRT) presented by Dr. Sadia Sadiq.
Historical context of SBRT as an evolution of Stereotactic Radiosurgery (SRS) and the need for extraordinary care in treatment.
Definition of SBRT, emphasizing image-guided, high-dose radiation for various tumors with demonstrated efficacy and acceptance of side effects.
Different radiation fractionation methods including standard, conventional hypofractionation, and stereotactic radiotherapy with relevant dose specifications.
Theoretical foundations supporting SBRT's application for metastatic lesions, including various scientific models addressing cancer growth.
Quality procedures required for SBRT, covering personnel qualifications, equipment assurance, and imaging techniques for accurate treatment.
Use of 4D CT simulators to account for tumor motion during treatment, including various motion management strategies.
Techniques to control breathing-related motion during SBRT treatment, including dampening, gating, and tracking systems.
Clinical experience and indications of SBRT in treating various tumors like lung, liver, spine, and pancreas, along with related clinical studies. Clinical outcomes of SBRT treatments, focusing on effectiveness, survival rates, and challenges faced in targeting liver tumors.
Application of SBRT in treating spinal tumors with emphasis on pain control, effective dose escalation, and observed patient outcomes.
SBRT use in prostate cancer treatment, including indications for low-risk and high-risk cancer cases.
Indications for SBRT in pancreatic cancer, the relevant challenges, and how it impacts treatment timelines.
Overview of side effects associated with SBRT across different organ systems and the importance of dose constraints.
Concluding access to the AAPM Task Group 101 report on SBRT, summarizing important findings.
Final thoughts on SBRT being referred to as the ultimate form of targeted therapy in radiation treatment.
Historical Perspective
We shouldrecognize and acknowledge
that Stereotactic Body Radiation
Therapy (SBRT) is an extension or
evolution of Stereotactic Radiosurgery
(SRS)
3.
Why ?
If weacknowledge this evolution, we
should also provide EXTRA-ORDINARY
CARE for SBRT as demanded in
Stereotactic Radiosurgery (SRS)
4.
Questions: Why isEXTRA-
ORDINARY
CARE necessary?
Why is EXTRA-ORDINARY
CARE needed ?
5.
Stereotactic body radiation
therapy(SBRT)
Management and delivery of image
-guided high-dose radiation therapy with
tumor-ablative intent within a course of
treatment that does not exceed 5
fractions American Society of Therapeutic Radiology and Oncology (ASTRO)
Also called SART
6.
Tumors include lung,liver, spine,
pancreas, kidney, and prostate.
Prospective trials have demonstrated
efficacy and acceptable acute and
subacute toxicities
Late toxicity requires further careful
assessment
7.
Radiation: Fractionation
Standard fractionation:
1.8-2.0 Gy a day, 5 days a week for 25-30
treatments
Conventional hypofractionation:
3-5 Gy a day, 5 days a week for 10-15
treatments
Stereotactic radiotherapy:
15-25 Gy a day, 1-3 days a week for 1-5
treatments
8.
Rationale of SBRT
Conceptual theories of cancer growth and
numerous lines of evidence behind use of SBRT
for metastatic lesions are
(a) The Empiric Or Phenomenological,
(B) The Patterns-of-failure Concept,
(C) The Theory Of Oligo metastases,
(D) A Lethal Burden Variation Of The Norton-simon
Hypothesis, Or
(E) Immunological Enhancement.
9.
Methods Of CellKill in SBRT
DNA damage
Anti Angiogenesis
Endothelial cell Apoptoses
10.
1. Qualifiedpersonnel:
a. Board-certified radiation oncologist b. Qualified medical physicist
c. Licensed radiation therapist d. Other support staff as indicated
(dosimetrists, oncology
2. Ongoing machine quality assurance
program;
3. Documentation in accordance with the ACR
Practice Guideline for Communication: Radiation Oncology;
4. Quality control of treatment accessories;
5. Quality control of planning and treatment
images;
6. Quality control of treatment planning
system;
7. Simulation and treatment systems based on
actual measurement of organ motion and setup
uncertainty.
11.
SBRT PHYSICS AND
TECHNOLOGY
1. CT simulation: Assess tumor motion
2. Immobilization: Minimize motion, breathing effects
3. Planning: Small field dosimetry considerations
4. Repositioning: High precision patient set-up:
Fiducial systems, IR/LED Active and Passive markers, US, Video
5. Relocalization: Identify tumor location in the treatment field:
* MV/ KV Xray, Implanted markers and/or set-up fiducials
* Motion tracking and gating systems
* Real-time tumor tracking systems with implanted markers
6. Treatment delivery techniques
Adapted conventional systems
Specialized SRT: Novalis, Cyberknife, Trilogy
12.
4D CT Simulator
Atechnique that allow an
evaluation of the
motion of the target
Figure: Christopher Willey, MD, PhD
13.
4D CT Simulator
Thetrace of the target motion
allow the creation of a
internal target volume
(ITV) for treatment
planning
Breathing-related motion controldevices
and systems fall into three general
categories:
(a) dampening,
(b) gating, and
(c) tracking or “chasing.”
16.
Respiratory dampening techniques
Include systems of abdominal compression intended to diminish
one of the largest contributors to breathing-related motion,
namely diaphragmatic excertion.
17.
ABC:
Also includedin this category are the systems employing breath-
holding maneuvers to stabilize the tumor in a reproducible stage
of the respiratory cycle (e.g., deep inspiration).
18.
Gating systems forSBRT
It follow the respiratory cycle using a surrogate
indicator for respiratory motion, for example, chest
wall motion, and employ an electronic beam activation
trigger allowing irradiation to occur only during a
specified range of expected tumor locations.
One importantobservation from the Indiana
University studies was that although the
treatment was generally well tolerated,
tumor location near large airways in the vicinity
of the pulmonary hilum (called the zone of the
proximal bronchial tree) was associated with a
markedly higher risk of toxicity.
24.
RTOG 0236:
•59 patients
•Median age 72
• All pts inoperable
•T1 – 80%; T2- 20%
•Dose: 60Gy in 3 fxs (BED 180)
Median FU 3 yrs:
•Local control = 97.6%
•Distant mets = 22.1%
•Overall survival @3yrs = 55.8%
•Median survival = 48 months
SBRT: LIVER
Underlyingsevere liver disease often renders
patients medically inoperable
Other nonsurgical therapies have generally
achieved at best rather modest success in that
setting.
29.
Challenges in TargetingLiver
Tumors
Limited visualization of the target
Liver deformation with respiration
Changes in GI organ luminal filling
Critical structures (stomach) may change in
shape and position between planning and
treatment
Interfraction target displacement with
respect to bony anatomy
First Liver SBRTExperience
50 patients treated to 75 lesions with SBRT for
primary and metastatic liver tumors
15 to 45 Gy, 1-5 fractions
Mean follow-up of 12 months
30% of tumors demonstrated growth arrest, 40% were
reduced in size, and 32% disappeared by imaging
studies
4 local failures (5.3%)
Mean survival time was 13.4 months
Blomgren, et. al., J Radiosurgery,
1998
34.
SBRT:SPINE
SBRT is anemerging technology used for the
treatment of spinal tumors.
Effective dose escalation
For patients who are not candidates for conventional
radiotherapy
To improve the quality of life for patients who may be
spared a prolonged treatment course.
Acute Radiation toxicity is reduced.
35.
Indications for SpinalSBRT
Pain control in vertebral metastases
Malignant Epidural Spinal Cord
compression
Benign Spinal Cord Tumors
36.
Dose volume constraints
In a Randomized trail of 260 patients investigators
have not observed a single case of Myelopathy at 1
year with dose of 8Gy *1fr.
Partial volume tolerance of the human spinal cord
to Radiosurgery was analyzed in 177 patients with
230 metastatic lesions.
The authors concluded that an acceptable estimate of
partial cord tolerance is 10 Gy to the 10% volume.
1.Rades D, Stalpers LJ, Veninga T et al. J Clin Oncol 23:3366–3375
2.Ryu S, Jin JY, Jin R et al 2007Cancer 109:628–636
37.
The a/bratio of Prostrate Cancer is lower than for
most other tumors. Values between 1.2 and 3 Gy
are suggested.
It is lower than surrounding normal tissues like
rectum (a/b of 4 Gy for late rectal sequelae).
It is hypothesized that hypofractionation if
accurately delivered increases the tumor control by
sparing surrounding late responding normal tissues.
SBRT:PROSTRATE
38.
Indications
Primary treatment fororgan confined low
risk prostrate cancer
Dose escalation for intermediate and high
risk prostrate cancer
SBRT: PANCREAS
Stereotactic bodyradiation therapy (SBRT) In
Pancreas is indicated for
1.Boderline resectable tumors to improve
resectability in Neo Adjuvuvant setting.
2.In Unresectable due to their lower life expectancy
to reduce 5 -6 weeks treatment to less than 5 days
3.In resectecd Ca Pancreas with positive margins.
41.
Challenges of SBRTin Pancreas
The head of the pancreas, where majority of tumors reside,
is in close proximity to the C-loop of the duodenum
Delivery of conventionally fractionated radiation (1.8–2
Gy/day) to more than 50 Gy results in damage to the small
bowel such as ulcerations, stenosis, bleeding, and
perforation.
The pancreas move with respiration, as well as with
peristalsis that is not easily predictable.
44.
SIDE EFFECTS
Radiobiology:
Tumorvs. Normal Tissue
Normal Tissue Toxicity
Lung: pneumonitis and fibrosis
Pancreas: duodenum and stomach
Spine lesions: cord
Prostate: rectum and bladder
Liver: normal liver (radiation induced liver
disease-RILD)